177 related articles for article (PubMed ID: 32185872)
1. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection.
Lipson EJ; Naqvi FF; Loss MJ; Schollenberger MD; Pardoll DM; Moore J; Brennan DC
Am J Transplant; 2020 Aug; 20(8):2264-2268. PubMed ID: 32185872
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral immunotherapy with anti-PD-1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts.
Dang N; Waer M; Sprangers B; Lin Y
Am J Transplant; 2021 Jan; 21(1):60-72. PubMed ID: 32506732
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients.
Hanania HL; Lewis DJ
J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250
[TBL] [Abstract][Full Text] [Related]
4. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Tsung I; Worden FP; Fontana RJ
Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy.
O'Connell KA; Schmults CD
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():45-48. PubMed ID: 34855241
[TBL] [Abstract][Full Text] [Related]
7. Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: A case report and review of literature.
Lu Z; Afzal M; Shirai K
Transpl Immunol; 2023 Dec; 81():101932. PubMed ID: 37734447
[TBL] [Abstract][Full Text] [Related]
8. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
9. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.
Aguirre LE; Guzman ME; Lopes G; Hurley J
Oncologist; 2019 Mar; 24(3):394-401. PubMed ID: 30413665
[TBL] [Abstract][Full Text] [Related]
12. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.
Owonikoko TK; Kumar M; Yang S; Kamphorst AO; Pillai RN; Akondy R; Nautiyal V; Chatwal MS; Book WM; Sahu A; Sica GL; Ahmed R; Ramalingam SS
Cancer Immunol Immunother; 2017 Jan; 66(1):45-50. PubMed ID: 27771741
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy.
Padala SA; Patel SK; Vakiti A; Patel N; Gani I; Kapoor R; Muhammad S
J Oncol Pharm Pract; 2021 Mar; 27(2):470-476. PubMed ID: 32580640
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Liver Allograft Injury in Patients With Donor-Derived Malignancy Treated With Immunosuppression Cessation and Retransplantation.
Lee BT; Ganjoo N; Fiel MI; Hechtman JF; Sarkar SA; Kim-Schluger L; Florman SS; Schiano TD
Am J Clin Pathol; 2022 Aug; 158(2):199-205. PubMed ID: 35285881
[TBL] [Abstract][Full Text] [Related]
15. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report.
Goldman JW; Abdalla B; Mendenhall MA; Sisk A; Hunt J; Danovitch GM; Lum EL
BMC Nephrol; 2018 Aug; 19(1):210. PubMed ID: 30126374
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
[TBL] [Abstract][Full Text] [Related]
17. Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration.
Lakhani L; Alasfar S; Bhalla A; Aala A; Rosenberg A; Ostrander D; Schollenberger MD; Brennan DC; Lipson EJ
Transplant Direct; 2021 Feb; 7(2):e656. PubMed ID: 33490381
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient.
Vidovic D; Simms GA; Pasternak S; Walsh M; Peltekian K; Stein J; Helyer LK; Giacomantonio CA
Front Immunol; 2021; 12():678028. PubMed ID: 34122442
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor therapy-associated graft intolerance syndrome in a failed kidney transplant recipient.
Mejia CD; Frank AM; Singh P; Yadav A
Am J Transplant; 2021 Mar; 21(3):1322-1325. PubMed ID: 32976688
[TBL] [Abstract][Full Text] [Related]
20. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.
Stevenson ML; Wang CQ; Abikhair M; Roudiani N; Felsen D; Krueger JG; Pavlick AC; Carucci JA
JAMA Dermatol; 2017 Apr; 153(4):299-303. PubMed ID: 28259107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
